epidermal-growth-factor and Pressure-Ulcer

epidermal-growth-factor has been researched along with Pressure-Ulcer* in 4 studies

Other Studies

4 other study(ies) available for epidermal-growth-factor and Pressure-Ulcer

ArticleYear
Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines.
    Mediators of inflammation, 2022, Volume: 2022

    To determine the clinical efficacy of recombinant human epidermal growth factor (rh-EGF) combined with povidone-iodine (PVI) on patients with pressure ulcers (PUs).. One hundred and five PU patients treated between January 2018 and January 2021 were enrolled and retrospectively analyzed. Of them, 50 patients who received conventional treatment were assigned to the control group (Con group), while 55 patients treated with rh-EGF combined with PVI were assigned to the observation group (Obs group). The two groups were compared in clinical efficacy, PU alleviation (total area reduction rate, total depth reduction rate, and total volume reduction rate), healing time, pain degree (Visual Analog Scale [VAS] score), inflammatory indexes (interleukin-8 [IL-8], tumor necrosis factor-. The Obs group yielded a higher total effective rate than the Con group (. All in all, rh-EGF combined with PVI has a definite curative effect on patients with PUs. It can promote PU alleviation and hydroxyproline secretion in the wound and inhibit pain and inflammatory reactions, which is worthy of clinical promotion.

    Topics: Cytokines; Epidermal Growth Factor; Humans; Hydroxyproline; Immunologic Factors; Inflammation; Pain; Povidone-Iodine; Pressure Ulcer; Retrospective Studies; Suppuration

2022
[Decubitus ulcer as the site of reactive soft tissue ossification--molecular biology aspects].
    Zentralblatt fur Chirurgie, 1996, Volume: 121 Suppl

    Topics: Epidermal Growth Factor; Gene Expression; Humans; Ossification, Heterotopic; Pressure Ulcer; RNA, Messenger; Skin

1996
Effects of epidermal growth factor on serum zinc and plasma prostaglandin E2 levels of mice with pressure sores.
    Prostaglandins, 1993, Volume: 45, Issue:2

    This work was undertaken to study the effects of systemic application of EGF on the plasma PGE2 and serum zinc levels of mice with pressure sores. The pressure sores were made on the hind limb of the mice by bilateral sciatic nerve neurotomy. Mice were injected IP, 1 microgram EGF daily for ten days, beginning on the 21st day after operation. EGF administration increased the serum zinc and plasma PGE2 levels compared with controls. These results indicate that EGF can be effective on wound healing by elevating the serum zinc and plasma PGE2 concentrations together with other physiological roles in cellular events.

    Topics: Animals; Denervation; Dinoprostone; Epidermal Growth Factor; Male; Mice; Pressure Ulcer; Sciatic Nerve; Wound Healing; Zinc

1993
Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
    Annals of plastic surgery, 1993, Volume: 30, Issue:2

    Topics: Administration, Topical; Becaplermin; Chronic Disease; Epidermal Growth Factor; Humans; Platelet-Derived Growth Factor; Pressure Ulcer; Proto-Oncogene Proteins c-sis; Recombinant Proteins

1993